

OrbusNeich x APCTO Club

Physician Exchange Program

16-17 March 2026 | Queen Elizabeth Hospital & Queen Mary Hospital, Hong Kong

Introduction

Dr. Hiromasa Katoh from Fukui Prefectural Hospital, Japan, was invited as the CTO case operator for a 1.5-day PEP held on 16–17 March 2026 in Hong Kong, in collaboration with APCTO Club and local consultants, Dr. Alan Chan and Dr. Frankie Tam, from Queen Elizabeth and Queen Mary Hospitals, alongside attending physicians including Dr. Michiya Kageyama from Nasu Red Cross Hospital, Dr. Hidenari Matsumura from Saiseikai Utsunomiya Hospital, and Dr. Eugene Wu, APCTO Club Director; three CTO cases were successfully performed, showcasing excellent angiographic outcomes and highlighting the strong performance and deliverability of the eucaLimus™ Drug-Eluting Stent and Support C™ Drug-coated Balloon during their first exposure to Japanese physicians.



The first OrbusNeich x APCTO Club collaboration through the Physician Exchange Program (PEP) was a great success at Queen Elizabeth Hospital, featuring Dr. Alan Chan, Dr. Hiromasa Katoh, and Dr. Eugene Wu.

Workshop Highlights

- The first case, a LAD CTO lesion, treated by antegrade-retrograde-antegrade strategy had achieved successful lesion crossing with eucaLimus™ stent 3.0 x 33 mm at mid-LAD and Support C™ 2.25 x 30 mm at mid to distal LAD.
- The second case, a proximal to mid LAD CTO was successfully completed via diagonal branch after prolonged antegrade and failed retrograde attempts. eucaLimus™ stent 3.0 x 38 mm and 3.5 x 28 mm were treated at prox-mid LAD while Support C™ 2.0 x 35 mm was treated at distal-LAD with excellent final angiographic result.
- Second day at Queen Mary Hospital, a LAD CTO case was successfully performed by Dr. Hiromasa Katoh and Dr. Frankie Tam with two eucaLimus™ stent 2.5 x 38 mm and 3.0 x 33 mm.

SUPPORT C™
Paclitaxel Coated PTCA Catheter

eucaLimus™
Coronary Stent System with Sirolimus Drug Coating



Dr. Hiromasa Katoh had performed a successful CTO case with Dr. Frankie Tam.

Overall, this collaboration have successfully demonstrated advanced CTO strategies and cross-institutional collaboration. The completion of three complex CTO cases with excellent angiographic outcomes underscored the strong performance, deliverability, and clinical value of eucaLimus™ Drug-Eluting Stent and Support C™ Drug-coated Balloon, marking a highly impactful first exposure to Japanese physicians.